Abnormal PDGFR signaling has been implicated in a variety of pathological conditions. Overexpression or mutation of PDGFR is associated with several types of cancer, including glioblastoma, sarcomas, and leukemias. Targeting PDGFR with specific inhibitors has become a therapeutic strategy in treating these cancers. Additionally, PDGFR is involved in the pathogenesis of fibrotic diseases such as pulmonary fibrosis and liver cirrhosis.
